Pfizer, Samsung Medical Center form liver cancer research partnership

NEW YORK Treatments for liver cancer could emerge from a new research partnership between the world’s largest drug maker and a medical center in Korea.

Pfizer and the Samsung Medical Center in Seoul announced Wednesday a collaboration to analyze tumors from Korean patients and generate genetic profiles that they said could direct therapies and improve the outcomes of liver cancer patients.

“We are pleased to have an opportunity to work with the world’s No. 1 pharmaceutical company, Pfizer, to better understand cancer in Korean patients, with the goal of being able to send a new message of hope for patients with liver cancer across the world, especially in Asia,” Samsung Medical Center president Choi Han-Yong said.